Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Career Feature
  • Published:

Career feature

As new cell and gene therapies emerge from academia, we must RISE to the opportunity

Nature Biotechnology volume 43, pages 143–146 (2025)Cite this article

Subjects

Academic medical centers must play a crucial part in overcoming cell and gene therapy development hurdles by establishing institutional frameworks that offer comprehensive support extending beyond financial assistance.

Access through your institution
Buy or subscribe

This is a preview of subscription content, access via your institution

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Different ways in which AMCs can drive translation of CGTs.
Fig. 2: AMCs can achieve funding sustainability by creating value and recapturing a part of it.

References

  1. Saez-Ibañez, A. R. et al. Nat. Rev. Drug Discov. 21, 631–632 (2022).

    Article  PubMed  Google Scholar 

  2. Kuzmin, D. A. et al. Nat. Rev. Drug Discov. 20, 173–174 (2021).

    Article  CAS  PubMed  Google Scholar 

  3. Vokinger, K. N., Avorn, J. & Kesselheim, A. S. N. Engl. J. Med. 388, 292–295 (2023).

    Article  PubMed  Google Scholar 

  4. Seyhan, A. A. Transl. Med. Commun. 4, 1–19 (2019).

    Article  Google Scholar 

  5. NEWDIGS Consortium at Tufts Medical Center. Are cell and gene therapy programs a better bet? Tufts Medical Center https://newdigs.tuftsmedicalcenter.org/wp-content/uploads/2023/10/NEWDIGS-Success-Rate-Comparison-2023F210v056.pdf (Tufts Medicine, 9 October 2023).

  6. Cohen, J. P. Science continues to outpace commericalization of cell and gene therapies. Forbes Newslett. https://www.forbes.com/sites/joshuacohen/2024/03/04/science-continues-to-outpace-commercialization-of-cell-and-gene-therapies/ (2024).

  7. RePORT. Estimates of funding for various research, condition, and disease categories (RCDC). NIH https://report.nih.gov/funding/categorical-spending#/ (14 May 2024).

  8. Kassir, Z., Sarpatwari, A., Kocak, B., Kuza, C. C. & Gellad, W. F. J. Am. Med. Assoc. 323, 890–891 (2020).

    Article  Google Scholar 

  9. Aiuti, A., Pasinelli, F. & Naldini, L. Nat. Med. 28, 1985–1988 (2022).

    Article  CAS  PubMed  Google Scholar 

  10. Fox, T. et al. Nat. Med. 29, 518–519 (2023).

    Article  CAS  PubMed  Google Scholar 

  11. Lee, N. K. & Chang, J. W. Ann. Lab. Med. 44, 314–323 (2024).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Scher, J. U. & Schett, G. Nat. Rev. Rheumatol. 17, 119–124 (2021).

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Gene and Cell Therapy Institute, Mass General Brigham, Cambridge, MA, USA

    Nandhitha Uma Naresh, Dana Hammill, Roger J. Hajjar & Nathan L. Yozwiak

  2. New York, NY, USA

    Mark Kessel

Authors
  1. Nandhitha Uma Naresh
    View author publications

    Search author on:PubMed Google Scholar

  2. Dana Hammill
    View author publications

    Search author on:PubMed Google Scholar

  3. Mark Kessel
    View author publications

    Search author on:PubMed Google Scholar

  4. Roger J. Hajjar
    View author publications

    Search author on:PubMed Google Scholar

  5. Nathan L. Yozwiak
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Nathan L. Yozwiak.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Uma Naresh, N., Hammill, D., Kessel, M. et al. As new cell and gene therapies emerge from academia, we must RISE to the opportunity. Nat Biotechnol 43, 143–146 (2025). https://doi.org/10.1038/s41587-024-02520-9

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/s41587-024-02520-9

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research